2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-149357
    Yhhu6669
    		Inhibitor
    Yhhu6669 is an anti-HBV agent. Yhhu6669 inhibits HBV DNA. Yhhu6669 inhibits HBV replication by inducing the formation of DNA-free capsids. Yhhu6669 decreases HBV DNA and HBcAg in AAV/HBV-infected mice. Yhhu6669 has favorable PK properties.
    Yhhu6669
  • HY-177667
    Tomligisiran
    		Inhibitor
    Tomligisiran is a siRNA in JNJ-3989 (JNJ-73763989). JNJ-3989 is comprised of 2 siRNAs (Daplusiran and Tomligisiran), that target hepatitis B virus (HBV) mRNAs for degradation, thereby inhibiting HBV replication.
    Tomligisiran
  • HY-148171
    L-2'-Fd4C
    		Inhibitor
    L-2'-Fd4C, is an l-nucleoside analogue. L-2'-Fd4C has anti-human immunodeficiency virus (HIV) and anti-hepatitis B virus (HBV) activity.
    L-2'-Fd4C
  • HY-145050
    HBV-IN-7
    		Inhibitor
    HBV-IN-7 is a potent HBV inhibitor with an EC50 of 7 nM (WO2021213445A1, compound 5).
    HBV-IN-7
  • HY-145051
    HBV-IN-8
    		Inhibitor
    HBV-IN-8 is a potent HBV inhibitor with an EC50 of 287.9 nM (WO2021213445A1, compound 13).
    HBV-IN-8
  • HY-13910R
    Tenofovir (Standard)
    		Inhibitor
    Tenofovir (Standard) is the analytical standard of Tenofovir. This product is intended for research and analytical applications. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).
    Tenofovir (Standard)
  • HY-156703S
    HBV-IN-39-d3
    		Inhibitor
    HBV-IN-39-d3 (Example 14) is a deuterated HBV-IN-39 (Example 13). HBV-IN-39 is an HBV inhibitor. HBV-IN-39-d3 has better oral bioavailability than HBV-IN-39.
    HBV-IN-39-d<sub>3</sub>
  • HY-145053A
    (5S,8R)-HBV-IN-10
    		Inhibitor
    (5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6.
    (5S,8R)-HBV-IN-10
  • HY-Z2862S
    Entecavir-13C2,15N-1
    		Inhibitor
    Entecavir-13C2,15N-1 is the 13C- and 15N-labeled Entecavir. Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.
    Entecavir-<sup>13</sup>C<sub>2</sub>,<sub>15</sub>N-1
  • HY-P4042
    Hepatitis B Virus Receptor Binding Fragment
    		Inhibitor
    Hepatitis B Virus Receptor Binding Fragment (hepatitis B peptide 4980) is a synthetic peptide analog which specifically binds to Hep G2 cells. Hepatitis B Virus Receptor Binding Fragment is a promising immunogen expected to elicit protective antibodies based on the concept of the attachment blockade pathway of virus neutralization.
    Hepatitis B Virus Receptor Binding Fragment
  • HY-131603
    Lamivudine triphosphate
    		Inhibitor
    Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA.
    Lamivudine triphosphate
  • HY-145713
    GS-8873
    		Inhibitor
    GS-8873 is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 causes neurofunctional deficits in rats and cynomolgus monkeys.
    GS-8873
  • HY-148781
    HBV-IN-30
    		Inhibitor
    HBV-IN-30 (ex44), a flavone derivative, is a potent covalently closed circular DNA (cccDNA) inhibitor. cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-30 has the potential for the research of HBV infection.
    HBV-IN-30
  • HY-161327
    HBV-IN-44
    		Inhibitor
    HBV-IN-44 (Compound (S)-2a) is a HBV inhibitor with a IC50 value of 23 nM for HbsAg. HBV-IN-44 is less toxic to the neurite growth of HT22 cells and DRG neurons in vitro.
    HBV-IN-44
  • HY-112142A
    (Rac)-AB-423
    		Inhibitor
    (Rac)-AB-423 (DVR-23) is an anti-HBV candidate compound with promising anti-HBV activity. (Rac)-AB-423 showed no induction of CYP1A2, CYP3A4, or CYP2B6 enzyme activity at high concentrations. (Rac)-AB-423 exhibited desirable pharmacokinetic properties, enabling good systemic exposure and high oral bioavailability. (Rac)-AB-423 achieved more than 2 log viral load reduction in the hydrodynamic injection (HDI) HBV mouse model.
    (Rac)-AB-423
  • HY-124364
    RO6889678
    		Inhibitor
    RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation.
    RO6889678
  • HY-N17557
    Schizanrin D
    		Inhibitor
    Schizanrin D (Schizarin D) is a C18 Dibenzocyclooctadiene lignin. Schizanrin D can be derived from dried stems of Kadsura matsudai. Schizanrin D inhibits HBeAg production. Schizanrin D is inactive in vitro against HIV replication.
    Schizanrin D
  • HY-N2988
    Schisanwilsonin C
    		Inhibitor
    Schisanwilsonin C (Arisanschinin K) shows anti-HBV activity.
    Schisanwilsonin C
  • HY-149392
    HBV-IN-35
    		Inhibitor
    HBV-IN-35 (Compound 88) is a HBV inhibitor. HBV-IN-35 has anti-HBV activities in mouse and human hepatocytes (EC50: 100 nM and 400 nM respectively).
    HBV-IN-35
  • HY-148783
    HBV-IN-32
    		Inhibitor
    HBV-IN-32 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-32 shows anti-HBV activity with an IC50 value of 0.14 µM for HBsAg. HBV-IN-32 inhibits cell growth.
    HBV-IN-32
Cat. No. Product Name / Synonyms Application Reactivity